AHR Stock Forecast & Price Target

American Healthcare REIT is attractive fundamentally because its core Trilogy-led ISHC platform, which contributes about 60% of NOI, is still producing mid-teens growth and benefits from occupancy gains, higher-acuity mix, value-based reimbursement, and private-pay strength. Its SHOP business is also scaling rapidly, rising to 22% of NOI as of 2Q26 and supported by 88.8% occupancy, strong pricing power, and a deep pipeline of accretive deals, including over $2.4B of closed and awarded investments. With net debt-to-EBITDA at 2.5x as of 2Q26, substantial liquidity, and limited near-term maturities, the company has both financial flexibility and earnings visibility to compound nFFO and NAV.

American Healthcare REIT is trading at a 4.7% implied cap rate, well below the 6.1%-6.2% healthcare average and the 7.0%-7.3% REIT average, suggesting the market is already paying a premium despite meaningful operating and regulatory risk. The company’s outlook is highly dependent on Trilogy, which generates over half of NOI and roughly half of Trilogy NOI comes from skilled nursing beds, leaving results exposed to Medicaid cuts, possible repeal of Indiana’s IGT add-on rates, labor pressure, and reimbursement volatility. Although recent sequential SSNOI growth of nearly 6% in ISHC and 5% in SHOP supports near-term momentum, the reliance on one tenant/operator, cost of capital sensitivity, and potential slowdown in the investment pace justify a negative stance.